Cargando…
Deleted in Liver Cancer 2 (DLC2) Was Dispensable for Development and Its Deficiency Did Not Aggravate Hepatocarcinogenesis
DLC2 (deleted in liver cancer 2), a Rho GTPase-activating protein, was previously shown to be underexpressed in human hepatocellular carcinoma and has tumor suppressor functions in cell culture models. We generated DLC2-deficient mice to investigate the tumor suppressor role of DLC2 in hepatocarcino...
Autores principales: | Yau, Tai On, Leung, Thomas Ho Yin, Lam, Sandra, Cheung, Oi Fung, Tung, Edmund Kwok Kwan, Khong, Pek Lan, Lam, Amy, Chung, Sookja, Ng, Irene Oi Lin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718616/ https://www.ncbi.nlm.nih.gov/pubmed/19668331 http://dx.doi.org/10.1371/journal.pone.0006566 |
Ejemplares similares
-
Upregulation of the Wnt Co-Receptor LRP6 Promotes Hepatocarcinogenesis and Enhances Cell Invasion
por: Tung, Edmund Kwok-Kwan, et al.
Publicado: (2012) -
Deleted in Liver Cancer 1 (DLC1) Utilizes a Novel Binding Site for Tensin2 PTB Domain Interaction and Is Required for Tumor-Suppressive Function
por: Chan, Lo-Kong, et al.
Publicado: (2009) -
Endothelial DLC1 is dispensable for liver and kidney function in mice
por: Tan, Ying, et al.
Publicado: (2020) -
Deleted in Liver Cancer 1 (DLC1) Negatively Regulates Rho/ROCK/MLC Pathway in Hepatocellular Carcinoma
por: Wong, Carmen Chak-Lui, et al.
Publicado: (2008) -
Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma
por: Wolosz, Dominika, et al.
Publicado: (2019)